SOURCE: IBC Life Sciences

August 27, 2007 10:00 ET

IBC'S ACT (Assays & Cellular Targets) 2007 to Feature Eight Keynote Presentations

WESTBOROUGH, MA--(Marketwire - August 27, 2007) - IBC announced today that its upcoming ACT (Assays & Cellular Targets) conference will feature eight keynote presentations in four conference tracks: G-Protein Coupled Receptors, Protein Kinase Targets, Assay & Screening Advances and Ion Channel Targets. ACT will be held October 17-19, 2007 at Loews Coronado Bay Resort in San Diego, CA.

Keynote presentations include:

--  "Unleashing the Kinome for Drug Discovery"
       Jessie M. English, Ph.D., Pfizer Research Technology Center
--  "Short QT - A New or an Old safety issue?"
       David J. Gallacher, BSc, Ph.D., Johnson & Johnson Pharmaceutical
        Research & Development
--  "State of the Stem Cell Market: Stem Cell Research 101"
       Eve Herold, Genetics Policy Institute
--  "Progress in Obtaining G-Protein Coupled Receptor Structures by X-ray
     Crystallography"
       Brian Kobilka, M.D., Stanford University
       Gebhard F. X. Schertler, Ph.D., MRC Laboratory of Molecular Biology
--  "Deciphering the Kinase Puzzle"
       Mark Namchuk, Vertex Pharmaceuticals
--  "Targeting Store-Operated Calcium Entry: CRAC Channels and
     STIM Sensors"
       Reinhold Penner, M.D., Ph.D., University of Hawaii
--  "Traveling through Time: Evolutionary and Ancient Records and their
     Implications in G Protein-coupled Receptor Research"
       Torsten Schöneberg, University of Leipzig, Germany
--  "Discovery and Validation of Secreted and Transmembrane Proteins as
     Therapeutic Targets"
       Tracy T. Tang, Ph.D., Genentech, Inc.

"Responding to industry demand, ACT 2007 offers the absolute latest scientific discoveries and advances in four key areas of scientific expertise," said Patrick Bayhylle, Research Director, IBC Life Sciences. "With the most academic presentations ever, eight keynotes and an unprecedented line up of speakers, ACT 2007 truly is THE most definitive event on Assays, Screening and Targets in the industry," said Bayhylle.

For questions about this conference, contact IBC at 800.390.4078 or visit the website at www.IBCLifeSciences.com/ACT.

Writers and editors are encouraged to attend. To request a press pass please contact Sarah Hershberger at shershberger@ibcusa.com

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. For more information, visit www.IBCLifeSciences.com.

Contact Information